Compare AOUT & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AOUT | SPRO |
|---|---|---|
| Founded | 2020 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.9M | 156.3M |
| IPO Year | 2020 | 2017 |
| Metric | AOUT | SPRO |
|---|---|---|
| Price | $12.95 | $1.19 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $12.50 | N/A |
| AVG Volume (30 Days) | 198.0K | ★ 1.5M |
| Earning Date | 03-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $190,536,000.00 | $66,802,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.06 | $300.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $6.26 | $1.10 |
| 52 Week High | $14.97 | $3.08 |
| Indicator | AOUT | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 52.67 | 18.94 |
| Support Level | $8.04 | N/A |
| Resistance Level | $14.97 | $2.44 |
| Average True Range (ATR) | 0.72 | 0.16 |
| MACD | -0.24 | -0.07 |
| Stochastic Oscillator | 19.12 | 6.19 |
American Outdoor Brands Inc is the provider of outdoor lifestyle products and shooting sports accessories encompassing hunting, fishing, meat processing, outdoor cooking, shooting, and personal security and defense products for rugged outdoor enthusiasts. It conceive, design, produce or source, and sell its outdoor lifestyle products including premium sportsman knives, land management tools, products used while hunting, meat processing equipment; and outdoor cooking products and hooting sports accessories, including rests, vaults, and other related accessories, electro-optical devices, including hunting optics, firearm aiming devices, flashlights, and laser grips, etc. The company operate as one reporting segment.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.